1.COVID-19 Dashboard (Johns Hopkins University, 2020); https://coronavirus.jhu.edu/map.html2.Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1–23 (2015).CAS PubMed PubMed Central Google Scholar 3.Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).CAS PubMed PubMed Central Google Scholar 4.McIntosh, K. & Perlman, S. in Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases 8th edn (eds Bennett, J. E. et al.) 1928–1936 (2015).5.Zhou, H. et al. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr. Biol. 30, 2196–2203 (2020).CAS PubMed PubMed Central Google Scholar 6.Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017–1032 (2020).CAS Google Scholar 7.Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).CAS PubMed PubMed Central Google Scholar 8.Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481 (2020).CAS PubMed PubMed Central Google Scholar 9.Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).CAS PubMed PubMed Central Google Scholar 10.Palaiodimos, L. et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 108, 154262 (2020).CAS PubMed PubMed Central Google Scholar 11.Ferdinand, K. C. & Nasser, S. A. African-American COVID-19 mortality: a sentinel event. J. Am. Coll. Cardiol. 75, 2746–2748 (2020).CAS PubMed PubMed Central Google Scholar 12.Killerby, M. E. et al. Characteristics associated with hospitalization among patients with COVID-19 – Metropolitan Atlanta, Georgia, March–April 2020. MMWR Morb. Mortal. Wkly Rep. 69, 790–794 (2020).CAS PubMed PubMed Central Google Scholar 13.Raisi-Estabragh, Z. et al. Greater risk of severe COVID-19 in Black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J. Public Health 42, 451–460 (2020). Google Scholar 14.Moore, J. T. et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5–18, 2020 – 22 states, February–June 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1122–1126 (2020).CAS PubMed PubMed Central Google Scholar 15.Mahajan, U. V. & Larkins-Pettigrew, M. Racial demographics and COVID-19 confirmed cases and deaths: a correlational analysis of 2886 US counties. J. Public Health 42, 445–447 (2020). Google Scholar 16.Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).CAS PubMed PubMed Central Google Scholar 17.Jager, S. et al. Global landscape of HIV–human protein complexes. Nature 481, 365–370 (2011).PubMed PubMed Central Google Scholar 18.Batra, J. et al. Protein interaction mapping identifies RBBP6 as a negative regulator of ebola virus replication. Cell 175, 1917–1930 (2018).CAS PubMed PubMed Central Google Scholar 19.Shah, P. S. et al. Comparative flavivirus-host protein interaction mapping reveals mechanisms of dengue and zika virus pathogenesis. Cell 175, 1931–1945 (2018).CAS PubMed PubMed Central Google Scholar 20.Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468 (2020).CAS PubMed PubMed Central Google Scholar 21.Niemann, H. H. et al. Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell 130, 235–246 (2007).CAS PubMed Google Scholar 22.Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).CAS PubMed PubMed Central Google Scholar 23.Xu, G. G., Guo, J. & Wu, Y. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications. Curr. Top. Med. Chem. 14, 1504–1514 (2014).CAS PubMed PubMed Central Google Scholar 24.Hayouka, Z. et al. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Natl Acad. Sci. USA 104, 8316–8321 (2007).CAS PubMed PubMed Central Google Scholar 25.Peat, T. S. et al. Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. PLoS ONE 7, e40147 (2012).CAS PubMed PubMed Central Google Scholar 26.Maginnis, M. S. Virus–receptor interactions: the key to cellular invasion. J. Mol. Biol. 430, 2590–2611 (2018).CAS PubMed PubMed Central Google Scholar 27.Daczkowski, C. M. et al. Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species. J. Mol. Biol. 429, 1661–1683 (2017).CAS PubMed PubMed Central Google Scholar 28.Yao, J. et al. Mechanism of inhibition of retromer transport by the bacterial effector RidL. Proc. Natl Acad. Sci. USA 115, E1446–E1454 (2018).CAS PubMed PubMed Central Google Scholar 29.Zhang, L. et al. Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1β. Proc. Natl Acad. Sci. USA 103, 13985–13990 (2006).CAS PubMed PubMed Central Google Scholar 30.Jonker, H. R. et al. Structural properties of the promiscuous VP16 activation domain. Biochemistry 44, 827–839 (2005).CAS PubMed Google Scholar 31.Card, G. L. et al. Crystal structure of a γ-herpesvirus cyclin-cdk complex. EMBO J. 19, 2877–2888 (2000).CAS PubMed PubMed Central Google Scholar 32.Smith, M., Honce, R. & Schultz-Cherry, S. Metabolic syndrome and viral pathogenesis: lessons from influenza and coronaviruses. J. Virol. 94, e00665-20 (2020).PubMed PubMed Central Google Scholar 33.Vidal, M. A unifying view of 21st century systems biology. FEBS Lett. 583, 3891–3894 (2009).CAS PubMed Google Scholar 34.Robinson, C. V., Sali, A. & Baumeister, W. The molecular sociology of the cell. Nature 450, 973–82. (2007).CAS PubMed Google Scholar 35.Barabasi, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56–68 (2011).CAS PubMed PubMed Central Google Scholar 36.Scott, D. E. et al. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–50. (2016).CAS PubMed Google Scholar 37.Arkin, M. R., Tang, Y. & Wells, J. A. Small-molecule inhibitors of protein–protein interactions: progressing toward the reality. Chem. Biol. 21, 1102–1114 (2014).CAS PubMed PubMed Central Google Scholar 38.Rooklin, D. et al. AlphaSpace: fragment-centric topographical mapping to target protein–protein interaction interfaces. J. Chem. Inf. Model. 55, 1585–1599 (2015).CAS PubMed PubMed Central Google Scholar 39.Lampson, B. L. & Davids, M. S. The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 12, 11–19 (2017).PubMed PubMed Central Google Scholar 40.Schormann, N. et al. Identification of protein–protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents. Antimicrob. Agents Chemother. 55, 5054–5062 (2011).CAS PubMed PubMed Central Google Scholar 41.White, P. W. et al. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1–E2 protein interaction. J. Biol. Chem. 278, 26765–26772 (2003).CAS PubMed Google Scholar 42.Goudreau, N. et al. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1–E2 protein–protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg. Med. Chem. 15, 2690–2700 (2007).CAS PubMed Google Scholar 43.Brito, A. F. & Pinney, J. W. Protein–protein interactions in virus–host systems. Front. Microbiol. 8, 1557 (2017).PubMed PubMed Central Google Scholar 44.Meyer, M. J. et al. Interactome INSIDER: a structural interactome browser for genomic studies. Nat. Methods 15, 107–114 (2018).CAS PubMed PubMed Central Google Scholar 45.Dominguez, C., Boelens, R. & Bonvin, A. M. HADDOCK: a protein–protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125, 1731–1737 (2003).CAS PubMed Google Scholar 46.van Zundert, G. C. P. et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720–725 (2016).PubMed Google Scholar 47.Chaudhury, S., Lyskov, S. & Gray, J. J. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics 26, 689–691 (2010).CAS PubMed PubMed Central Google Scholar 48.Kirchdoerfer, R. N. et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 15701 (2018).PubMed PubMed Central Google Scholar 49.Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894–904 (2020).CAS PubMed PubMed Central Google Scholar 50.Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat. Struct. Mol. Biol. 27, 763–767 (2020).CAS PubMed PubMed Central Google Scholar 51.Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).CAS PubMed PubMed Central Google Scholar 52.Alford, R. F. et al. The Rosetta all-atom energy function for macromolecular modeling and design. J. Chem. Theory Comput. 13, 3031–3048 (2017).CAS PubMed PubMed Central Google Scholar 53.Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).CAS PubMed PubMed Central Google Scholar 54.Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).CAS PubMed PubMed Central Google Scholar 55.Jordan, R. E. & Adab, P. Who is most likely to be infected with SARS-CoV-2? Lancet Infect. Dis. 20, 995–996 (2020).CAS PubMed PubMed Central Google Scholar 56.Cao, Y. et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 11 (2020).CAS PubMed PubMed Central Google Scholar 57.Darbeheshti, F. & Rezaei, N. Genetic predisposition models to COVID-19 infection. Med. Hypotheses 142, 109818 (2020).CAS PubMed PubMed Central Google Scholar 58.Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 202, 756–759 (2020).CAS PubMed PubMed Central Google Scholar 59.Kortemme, T. & Baker, D. A simple physical model for binding energy hot spots in protein–protein complexes. Proc. Natl Acad. Sci. USA 99, 14116–14121 (2002).CAS PubMed PubMed Central Google Scholar 60.Shulman-Peleg, A. et al. Spatial chemical conservation of hot spot interactions in protein–protein complexes. BMC Biol. 5, 43 (2007).PubMed PubMed Central Google Scholar 61.Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).CAS PubMed PubMed Central Google Scholar 62.Suryamohan, K. et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun. Biol. 4, 475 (2021).CAS PubMed PubMed Central Google Scholar 63.Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261–1265 (2020).CAS PubMed PubMed Central Google Scholar 64.Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).CAS PubMed PubMed Central Google Scholar 65.Pieper, U. et al. ModBase, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res. 42, D336–D346 (2014).CAS PubMed Google Scholar 66.Guharoy, M. & Chakrabarti, P. Conserved residue clusters at protein–protein interfaces and their use in binding site identification. BMC Bioinf. 11, 286 (2010). Google Scholar 67.Gupta, R. et al. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: insights into functional evolution and human genomics. J. Biol. Chem. 295, 11742–11753 (2020).CAS PubMed PubMed Central Google Scholar 68.Stenson, P. D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577–581 (2003).CAS PubMed Google Scholar 69.Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).CAS PubMed Google Scholar 70.Buniello, A. et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).CAS PubMed PubMed Central Google Scholar 71.Yang, J. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J. Infect. Dis. 94, 91–95 (2020).CAS PubMed PubMed Central Google Scholar 72.Sahni, N. et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161, 647–660 (2015).CAS PubMed PubMed Central Google Scholar 73.Wang, X. et al. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat. Biotechnol. 30, 159–64. (2012).CAS PubMed PubMed Central Google Scholar 74.Sim, N. L. et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 40, W452–W457 (2012).CAS PubMed PubMed Central Google Scholar 75.Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).CAS PubMed PubMed Central Google Scholar 76.Yu, H. et al. High-quality binary protein interaction map of the yeast interactome network. Science 322, 104–110 (2008).CAS PubMed PubMed Central Google Scholar 77.Braun, P. et al. An experimentally derived confidence score for binary protein–protein interactions. Nat. Methods 6, 91–97 (2009).CAS PubMed Google Scholar 78.Vo, T. V. et al. A proteome-wide fission yeast interactome reveals network evolution principles from yeasts to human. Cell 164, 310–323 (2016).CAS PubMed PubMed Central Google
https://www.nature.com/articles/s41592-021-01318-w
A 3D structural SARS-CoV-2–human interactome to explore genetic and drug perturbations
